Neogap is granted Australian patent for innovative method of MS treatment and diagnosis
The Swedish biotechnology company Neogap Therapeutics, which develops personalised immunotherapy, has been granted a patent in Australia for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS). The patent strengthens Neogap's strategic intellectual property portfolio and marks an important step in the company's efforts to develop groundbreaking treatments for autoimmune diseases such as MS.
The patent covers a tolerogenic treatment method for multiple sclerosis (MS). The method utilises specially designed molecules to influence the immune system's response, conditioning it to tolerate the body's cells instead of mistakenly attacking them. Correcting the immune system's misguided reactions is crucial in treating MS. The patent is valid until 2038.
By integrating the method with its EpiTCer® technology, Neogap can forge improved treatment methods and diagnostic processes for MS. This amalgamation of patented method and advanced technology unlocks new possibilities for devising innovative and targeted treatment strategies against the disease.
"The new patent marks a milestone that not only strengthens our IP portfolio but also reflects the great potential of our EpiTCer® platform," says Samuel Svensson, CEO of Neogap Therapeutics. "While our primary focus remains on cancer treatment, this patent also signifies an exciting expansion of our research into other vital areas, including MS, where we see considerable potential for our EpiTCer® technology. This development allows us to build further on our previous successes in identifying specific molecular markers for MS diagnosis and take an important step forward in our research and development of innovative treatments for autoimmune diseases."
Beyond its application in MS treatment, the patent also incorporates methods for diagnosing MS, thus improving the prospects for early detection and treatment of the disease. The inventors are Associate Professor Hans Grönlund, CSO and founder of Neogap, and Mattias Bronge, MD, PhD.
About EpiTCer®
EpiTCer® is a patented method that enables the detection and analysis of antigen-specific, autoreactive T-cells. The technology is being utilised in the company's ongoing Phase I/II clinical trial of personalised immunotherapy for colorectal cancer. Additionally, EpiTCer® holds the potential to be used in other diseases and conditions where the immune system is either overreactive or insufficiently sensitive, such as infectious diseases, autoimmune diseases, and allergies.
For more information, please contact:
Samuel Svensson, CEO
Email: samuel.svensson@neogap.se
Phone: +46 733 54 21 94
About Neogap Therapeutics
Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit the company's website at neogap.se and follow Neogap on LinkedIn.
Tags:
